A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells

Translational Stroke Research

Volumn 3, Issue 1, 2012, Pages 90-98

  Glover, Loren E ^a   Tajiri, Naoki ^a   Weinbren, Nathan L ^a   Ishikawa, Hiroto ^a   Shinozuka, Kazutaka ^a   Kaneko, Yuji ^a   Watterson, D Martin ^b   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cell therapy; Drug treatment; Endothelial progenitor cells; Stroke; Translational research

Indexed keywords

ALBUMIN; MINOCYCLINE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD BRAIN BARRIER; CLINICAL EFFECTIVENESS; ENDOTHELIAL PROGENITOR CELL; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; TRANSLATIONAL RESEARCH;

EID: 84857640661     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0127-8     Document Type: Review

References (88)

1. Borlongan CV, Chopp M, Steinberg GK, Bliss TM, Li Y, Lu M, et al. Potential of stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic. Regen Med. 2008; 3: 249-50.
2. Chopp M, Steinberg GK, Kondziolka D, Lu M, Bliss TM, Li Y, et al. Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplant. 2009; 18: 691-3.
3. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009; 40: 510-5.
4. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000; 55: 565-9.
5. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood. 2003; 102: 3483-93.
6. Munoz-Elias G, Woodbury D, Black IB. Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor function. Stem Cells. 2003; 21: 437-48.
7. Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu SJ, et al. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Prog Neurobiol. 2008; 85: 318-34.
8. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother. 2008; 8: 1193-201.
9. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif. 2008; 1: 94-114.
10. Lapidot T, Kollet O. The brain-bone-blood triad: traffic lights for stem-cell homing and mobilization. Hematol Am Soc Hematol Educ Program. 2010; 2010: 1-6.
11. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005; 106: 1901-10.
12. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem. 2006; 99: 690-70.
13. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood. 2008; 111: 3923-30.
14. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 2006; 34: 967-75.
15. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Tissue Kinet. 1997; 3: 393-403.
16. Gronthos S, Simmons PJ. The biology and application of human bone marrow stromal cell precursors. J Hematother. 1996; 5: 15-23.
17. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone. 1992; 13: 69-80.
18. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci. 2000; 113: 1161-6.
19. Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA. 1999; 95: 1142-7.
20. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276: 71-4.
21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-7.
22. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221-8.
23. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002; 109: 625-37.
24. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105: 71-7.
25. McCarty JH. Cell adhesion and signaling networks in brain neurovascular units. Curr Opin Hematol. 2009; 16: 209-14.
26. Lapergue B, Mohammad A, Shuaib A. Endothelial progenitor cells and cerebroascular diseases. Prog Neurobiol. 2007; 83: 349-62.
27. Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K, Otem M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000; 95: 3106-12.
28. Rustemeyer P, Wittkowski W, Jurk K, Koller A. Optimized flow cytometric analysis of endothelial progenitor cells in peripheral blood. J Immunoass Immunochem. 2006; 27: 77-88.
29. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434-8.
30. Kocher AA, Schuster MD, Bonaros N, Lietz K, Xiang G, Martens TP, et al. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J Mol Cell Cardiol. 2006; 40: 455-64.
31. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke. 2004; 35: 2385-9.
32. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997; 64: 278-94.
33. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun. 2008; 30: 121-7.
34. Sordi V, Piemonti L. Mesenchymal stem cells as feeder cells for pancreatic islet transplants. Rev Diabetes Stud. 2010; 7: 132-43.
35. Hamada S, Satoh K, Hirota M, Kanno A, Umino J, Ito H, et al. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol. 2011;(in press).
36. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol. 2000; 28: 707-15.
37. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA. 2010; 107: 5652-7.
38. Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM. Lack of telomerase activity in human mesenchymal stem cells. Leukemia. 2003; 17: 1146-9.
39. Wang D, Shen W, Zhang F, Chen M, Chen H, Cao K. Connexin43 promotes survival of mesenchymal stem cells in ischaemic heart. Cell Biol Int. 2010; 34: 415-23.
40. Liang H, Hou H, Yi W, Yang G, Gu C, Lau WB, et al. Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury. Eur Heart J. 2011;(in press).
41. Ko IK, Kim BG, Awadallah A, Mikulan J, Lin P, Letterio JJ, et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther. 2010; 18: 1365-72.
42. Kobune M, Kawano Y, Ito Y, Chiba H, Nakamura K, Tsuda H, et al. Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobble-stone area-supporting cells. Exp Hematol. 2003; 31: 715-22.
43. Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. Blood. 2004; 103: 1647-52.
44. Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis. 2011, 164608.
45. Sokal EM. From hepatocytes to stem and progenitor cells for liver regenerative medicine: advances and clinical perspectives. Cell Prolif. 2011; 44: 39-43.
46. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, et al. A population of very small embryonic-like (VSEL) CXCR4 (+) SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 2006; 20: 857-69.
47. Zuba-Surma EK, Kucia M, Wu W, Klich I, Lillard Jr JW, Ratajczak J, et al. Very small embryonic-like stem cells are present in adult murine organs: Image Stream-based morphological analysis and distribution studies. Cytometry A. 2008; 73A: 1116-27.
48. Kucia M, Halasa M, Wysoczynski M, Baskiewicz-Masiul M, Moldenhawer S, Zuba-Surma E, et al. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia. 2007; 21: 297-303.
49. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005; 57: 874-82.
50. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001; 189: 49-57.
51. Chen J, Wang L, Zhang Z, Lu D, Lu M, Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001; 32: 1005-11.
52. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol. 2002; 1: 92-100.
53. Li Y, Chen J, Chopp M. Adult bone marrow transplantation after stroke in adult rats. Cell Transplant. 2001; 10: 31-40.
54. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, et al. Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology. 2002; 59: 514-23.
55. Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M, et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia. 2005; 49: 407-17.
56. Rempe DA, Kent TA. Using bone marrow stromal cells for treatment of stroke. Neurology. 2002; 59: 486-7.
57. Song S, Kamath S, Mosquera D, Zigova T, Sanberg P, Vesely DL, et al. Expression of brain natriuretic peptide by human bone marrow stromal cells. Exp Neurol. 2004; 185: 191-7.
58. Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G, et al. Transplantation of bone marrow-derived stem cells: a promising therapy for stroke. Cell Transplant. 2007; 16: 159-69.
59. Kucia M, Ratajczak J, Ratajczak MZ. Are bone marrow stem cells plastic or heterogenous-that is the question. Exp Hematol. 2005; 33: 613-23.
60. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell- based vascular therapy. Circulation. 2003; 108: 2710-5.
61. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Egucji H, et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000; 105: 1527-36.
62. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000; 95: 952-8.
63. Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Tervaert JW, Lodder J. Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts. Stroke. 2008; 39: 2158-65.
64. Nishimura N, Schaffer CB, Friedman B, Tsai PS, Lyden PD, Kleinfeld D. Targeted insult to subsurface cortical blood vessels using ultrashort laser pulses: three models of stroke. Nat Methods. 2006; 3: 99-108.
65. Rivers CS, Wardlaw JM, Armitage PA, Bastin ME, Carpenter TK, Cvoro V, et al. Persistent infarct hyperintensity on diffusion-weighted imaging late after stroke indicates heterogeneous, delayed, infarct evolution. Stroke. 2006; 37: 1418-23.
66. Ay H, Arsava EM, Rosand J, Furie KL, Singhal AB, Schaefer PW, et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke. 2008; 39: 1409-13.
67. Stoeckel MC, Wittsack HJ, Meisel S, Seitz RJ. Pattern of cortex and white matter involvement in severe middle cerebral artery ischemia. J Neuroimaging. 2007; 17: 131-40.
68. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004; 8: 498-508.
69. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, et al. Circulating cd34-positive cells provide an index of cerebrovascular function. Circulation. 2004; 109: 2972-5.
70. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005; 106: 1525-31.
71. Schatteman GC, Awad O. Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol. 2004; 276: 13-21.
72. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2005; 56: 79-101.
73. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998; 91: 3527-61.
74. Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et al. Endothelial progenitor cells during cerebrovascular disease. Stroke. 2005; 36: 151-3.
75. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593-600.
76. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott RB, Emerich DF. Intracerebral transplantation of porcine choroid plexus provides structural and functional neuroprotection in a rodent model of stroke. Stroke. 2004; 35: 2206-10.
77. Bliss TM, Kelly S, Shah AK, Foo WC, Kohli P, Stokes C, et al. Transplantation of hNT neurons into the ischemic cortex: cell survival and effect on sensorimotor behavior. J Neurosci Res. 2006; 83: 1004-14.
78. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol. 2007; 62: 49-58.
79. Manaenko A, Chen H, Kammer J, Zhang JH, Tang J. Comparison Evans Blue injection routes: Intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model. J Neurosci Methods. 2011; 195: 206-10.
80. Chopp M, Zhang ZG, Jiang Q. Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke. 2007; 38: 827-31.
81. Guzman R, Uchida N, Bliss TM, He D, Christopherson KK, Stellwagen D, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci USA. 2007; 104: 10211-6.
82. Schumacher AM, Velentza AV, Watterson DM. Death-associated protein kinase as a potential therapeutic target. Expert Opin Ther Targets. 2002; 6: 497-506.
83. Schumacher AM, Velentza AV, Watterson DM, Wainwright MS. DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim Biophys Acta. 2002; 1600: 128-37.
84. Velentza AV, Wainwright MS, Zasadzki M, Mirzoeva S, Schumacher AM, Haiech J, et al. An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett. 2003; 13: 3465-70.
85. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D. Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem. 2005; 280: 42290-9.
86. Kang BN, Ahmad AS, Saleem S, Patterson RL, Hester L, Dore S, et al. Death-associated protein kinase-mediated cell death modulated by interaction with DANGER. J Neurosci. 2010; 30: 93-8.
87. Borlongan CV. Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all! Leukemia. 2011. doi: 10. 1038/leu. 2011. 167.
88. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: Therapeutic implications for stroke and other neurological disorders. Prog Neurobiology. 2011;(in press).